Lung Cancer Ntnu The research group has established a large network of hospitals in northern europe who are actively participating in the research activity. our main aim is to provide better, more targeted and individualized cancer treatment for sclc patients. About 40% of all newly discovered cases of lung cancer have metastatic disease which has traditionally been considered as an incurable situation. four courses of platinum based chemotherapy have been standard for patients with advanced nsclc.
New Ntnu Method For Accurately Detecting Lung Cancer We describe the national trends in characteristics and survival, and geographical differences in diagnostic workup, treatment, and survival for patients with small cell lung cancer (sclc). Lc is the second most frequent cancer in both sexes, after prostate and breast cancer, but by far the most common cause of cancer deaths. owing to a steady increase in survival, the prevalence has tripled over the last 20 years, and is now 3.5 times as high as the incidence (fig. 2 ). Lung cancer has been the most common cancer type for several decades with a low survival rate worldwide. smoking is the most important risk factor for lung cancer, which accounts for 80 90 % of all lung cancer cases. Learn more about our completed lung cancer projects. lung cancer is the deadliest cancer, causing more years of life lost than the other three most common cancers altogether (breast, prostate and colon cancer). small cell lung cancer (sclc) accounts for 13 15% of lung cancer cases.
New Ntnu Method For Accurately Detecting Lung Cancer Lung cancer has been the most common cancer type for several decades with a low survival rate worldwide. smoking is the most important risk factor for lung cancer, which accounts for 80 90 % of all lung cancer cases. Learn more about our completed lung cancer projects. lung cancer is the deadliest cancer, causing more years of life lost than the other three most common cancers altogether (breast, prostate and colon cancer). small cell lung cancer (sclc) accounts for 13 15% of lung cancer cases. Bjørn henning grønberg professor of oncology verifisert e postadresse på ntnu.no startside lung cancer main interest sclc artikler 1–20. Randomized phase ii trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Physician and specialist in oncology, both medical oncology and radiotherapy. main research activity is international, randomized, clinical intervention trials in lung cancer, especially small cell lung cancer (sclc). Better knowledge of the biology of non small cell lung cancer (nsclc) has enabled us to move from “one size fits all” chemotherapy to specific therapy for subgroups characterized by biomarkers. this has been key for improving nsclc survival in recent years.
Comments are closed.